Skip to content
Buy This GLP
← Research
Evidence

Comorbidities in Weight-Loss Drug Users: Norwegian Registry of 190,818 Starters

A Norwegian registry study found more recorded coexisting conditions among people starting a weight-loss drug than among age- and sex-matched controls.

Editorial profile: Carla MedinaBuy This GLP Editorial Team7 min read
Users vs matched controlsuserscontrolsany comorbidity74%50%hypertension35%18%opioid dispensed27%14%antidepressant22%10%sleep apnea9%2%Midpoints of ranges spanning five different drugs.

Studies of who receives GLP-1 treatment can reflect different health systems. Researchers used Norwegian registries to describe what diagnoses people had before starting one of five weight-loss medicines [1].

Who was included

The study followed adults aged 18 to 74 who started one of the medicines in 2023 or 2024 (n = 190,818). Researchers matched each to five population controls by age and sex. They checked diagnoses from the prior two years and medicines dispensed in the prior year.

Between 71% and 78% of starters had at least one recorded coexisting condition. Among controls, the range was 49% to 51%. The ranges show variation across the five drug groups [1].

Which conditions were recorded

High blood pressure was recorded in 32% to 38% of starters and 17% to 20% of controls. The corresponding ranges for sleep apnea were 7% to 11% and 2% to 3%.

Trials of GLP-1 treatment for sleep apnea ask a different question about treatment outcomes. This registry study measured diagnoses that preceded treatment.

Opioids and antidepressants were also dispensed more often before treatment in the starter groups. Dispensing records cannot confirm why a drug was prescribed or whether it was taken. The Norwegian results do not establish the health profile of U.S. telehealth patients.

Frequently asked

What percentage had a coexisting condition?
Across the five drug groups, 71% to 78% of starters had at least one recorded condition. The matched control groups ranged from 49% to 51%.

Sources

  1. [1] Bakken IJ, Ruiz PL, Furu K, Gulseth HL, et al. (2026). Clinical Characteristics of Users of Weight Loss Drugs: Population-Based Case-Control Study Diabetes, Obesity & Metabolism. PMID 42086462

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence